BDR denied compulsory license request for Bristol drug, Economic Times says The Indian Patent Office has rejected BDR Pharmaceutical's application for compulsory license on Bristol Myers' cancer drug dasatinib, according to Economic Times, citing an affidavit filed by Bristol Myers. Reference Link
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Vertex, Regeneron speculated to be merger targets, TheStreet says Among the predictions for the biotech sector in 2014 made by David Sobek of TheStreet.com was a call for "at least two" mergers between large-cap companies. Sobek predict Sanofi (SNY) will buy Regeneron (REGN) and that Bristol-Myers Squibb (BMY) will acquire Vertex Pharmaceuticals (VRTX). Reference Link